Jasper Therapeutics reported a significant net loss of $148.4 million for the nine months ended September 30, 2026, primarily driven by a $129.5 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity through a financing and acquisition, ending the period with $135.3 million in cash and cash equivalents.
Jasper Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update following its acquisition of Kira Pharmaceuticals. The company highlighted progress in its Phase 2 renal basket study for vensobafusp alfa (KP104), including completed enrollment in the IgA nephropathy cohort and the dosing of the first patient with IC-MPGN.
“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN).”
Jeet Mahal, President and Chief Executive Officer of Jasper
“We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”
Jeet Mahal, President and Chief Executive Officer of Jasper
Jasper Therapeutics convened and then adjourned its special meeting of stockholders due to the lack of a quorum. The meeting has been rescheduled to reconvene virtually on December 1, 2026, with no changes to the proposals or the record date.
Jasper Therapeutics completed a tender offer to repurchase 8,510,658 of its outstanding warrants at a price of $0.324 per warrant. The company will pay an aggregate of approximately $2.76 million in cash for the tendered warrants, which represent roughly 68.94% of the outstanding warrants issued in September 2025.
Jasper Therapeutics announced a 1-for-30 reverse stock split of its common stock, effective November 6, 2026. The split will reduce the number of outstanding shares from approximately 33.3 million to 1.1 million to increase the per-share trading price on the Nasdaq Capital Market. The authorized number of shares remains unchanged at 490 million, resulting in an increase in authorized but unissued shares available for future use.
Jasper Therapeutics completed enrollment for the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104). The company expects to report initial interim data from this study by year-end 2026 and plans to expand the study to include patients with focal segmental glomerulosclerosis (FSGS) in early 2027.
Jasper Therapeutics has commenced a cash tender offer to repurchase all 12,345,707 of its outstanding warrants issued in September 2025 at a price of $0.324 per warrant. The company expects to pay approximately $4.0 million if all warrants are tendered, aiming to reduce potential share dilution and simplify its capital structure.
Jasper Therapeutics stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-15 and 1-for-35. Stockholders also approved increasing the total number of authorized shares of common stock from 490 million to 675 million.
Jasper Therapeutics M&A Deal with Kira Pharmaceuticals
Jasper Therapeutics filed an amendment to provide required financial statements and pro forma information regarding its completed acquisition of Kira Pharmaceuticals. The deal involved the issuance of approximately 5.2 million common shares and 4.6 million preferred shares to Kira shareholders, alongside a concurrent $132 million private placement financing.
Jasper Therapeutics M&A Deal with Kira Pharmaceuticals
Jasper Therapeutics, Inc. filed an amendment to its previous 8-K to include required financial statements and pro forma information following its completed acquisition of Kira Pharmaceuticals. The transaction was structured as a merger where Kira merged into a wholly owned subsidiary of Jasper, and the filing also references a concurrent private placement of preferred stock and a license agreement with Mirador.
Herb Cross resigned as CFO, Principal Financial Officer, and Principal Accounting Officer of Jasper Therapeutics effective October 9, 2026. The company appointed CEO Jeet Mahal as interim Principal Financial Officer and Rick Ruiz as interim Principal Accounting Officer to fill the vacancies.